维奈克拉治疗复发或难治性非霍奇金淋巴瘤的I期首次人体研究
该I期首次人体研究纳入106例复发或难治性非霍奇金淋巴瘤患者,给予维奈克拉每日一次口服,目标剂量200至1200 mg,采用剂量递增和安全性扩展队列。维奈克拉总体耐受良好,常见3至4级不良事件为血液学毒性;总缓解率44%(套细胞淋巴瘤75%、滤泡性淋巴瘤38%、弥漫大B细胞淋巴瘤18%),估计中位无进展生存期6个月。
要点
- 维奈克拉在复发或难治性非霍奇金淋巴瘤中总体耐受良好,未观察到临床肿瘤溶解综合征。
- 总缓解率44%(套细胞淋巴瘤75%、滤泡性淋巴瘤38%、弥漫大B细胞淋巴瘤18%)。
- 估计中位无进展生存期6个月(套细胞淋巴瘤14个月、滤泡性淋巴瘤11个月、弥漫大B细胞淋巴瘤1个月)。
核心结论
- 选择性靶向BCL-2的维奈克拉耐受良好,单药活性在不同非霍奇金淋巴瘤亚型间存在差异。
- 确定1200 mg为未来滤泡性淋巴瘤和弥漫大B细胞淋巴瘤研究的推荐单药剂量,800 mg足以在套细胞淋巴瘤中持续获得持久缓解。
- 包括联合治疗以提高缓解率和持久性的进一步研究正在进行中。
研究设计与样本
- I期首次人体研究,纳入106例复发或难治性非霍奇金淋巴瘤患者,接受维奈克拉每日一次口服直至疾病进展或不可接受毒性,目标剂量200至1200 mg,设剂量递增和安全性扩展队列。
- 大多数剂量递增队列患者及所有安全性扩展患者以3周剂量爬坡期开始治疗。
主要发现
- 非霍奇金淋巴瘤亚型包括套细胞淋巴瘤(n=28)、滤泡性淋巴瘤(n=29)、弥漫大B细胞淋巴瘤(n=34)、由慢性淋巴细胞白血病转化的弥漫大B细胞淋巴瘤(Richter转化;n=7)、华氏巨球蛋白血症(n=4)和边缘区淋巴瘤(n=3)。
- 未观察到临床肿瘤溶解综合征,3例患者记录到实验室肿瘤溶解综合征。
- 103例(97%)报告治疗中出现的不良事件,多数为1至2级;59例(56%)报告3至4级事件,最常见为血液学毒性,包括贫血(15%)、中性粒细胞减少(11%)和血小板减少(9%)。
- 总缓解率为44%(套细胞淋巴瘤75%、滤泡性淋巴瘤38%、弥漫大B细胞淋巴瘤18%)。
- 估计中位无进展生存期为6个月(套细胞淋巴瘤14个月、滤泡性淋巴瘤11个月、弥漫大B细胞淋巴瘤1个月)。
关键数值与推荐
- 推荐未来在滤泡性淋巴瘤和弥漫大B细胞淋巴瘤中研究的单药剂量为1200 mg。
- 800 mg足以在套细胞淋巴瘤中持续获得持久缓解。
临床怎么用
- 作者认为,维奈克拉单药在复发或难治性非霍奇金淋巴瘤中耐受良好,单药活性因亚型而异。
- 作者确定1200 mg为未来滤泡性淋巴瘤和弥漫大B细胞淋巴瘤研究的推荐单药剂量,800 mg足以在套细胞淋巴瘤中持续获得持久缓解。
- 作者指出包括联合治疗以提高缓解率和持久性的进一步研究正在进行中。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose B-cell leukemia/lymphoma-2 (BCL-2) overexpression is common in many non-Hodgkin lymphoma (NHL) subtypes. A phase I trial in patients with NHL was conducted to determine safety, pharmacokinetics, and efficacy of venetoclax, a selective, potent, orally bioavailable BCL-2 inhibitor. Patients and Methods A total of 106 patients with relapsed or refractory NHL received venetoclax once daily until progressive disease or unacceptable toxicity at target doses from 200 to 1,200 mg in dose-escalation and safety expansion cohorts. Treatment commenced with a 3-week dose ramp-up period for most patients in dose-escalation cohorts and for all patients in safety expansion. Results NHL subtypes included mantle cell lymphoma (MCL; n = 28), follicular lymphoma (FL; n = 29), diffuse large B-cell lymphoma (DLBCL; n = 34), DLBCL arising from chronic lymphocytic leukemia (Richter transformation; n = 7), Waldenström macroglobulinemia (n = 4), and marginal zone lymphoma (n = 3). Venetoclax was generally well tolerated. Clinical tumor lysis syndrome was not observed, whereas laboratory tumor lysis syndrome was documented in three patients. Treatment-emergent adverse events were reported in 103 patients (97%), a majority of which were grade 1 to 2 in severity. Grade 3 to 4 events were reported in 59 patients (56%), and the most common were hematologic, including anemia (15%), neutropenia (11%), and thrombocytopenia (9%). Overall response rate was 44% (MCL, 75%; FL, 38%; DLBCL, 18%). Estimated median progression-free survival was 6 months (MCL, 14 months; FL, 11 months; DLBCL, 1 month). Conclusion Selective targeting of BCL-2 with venetoclax was well tolerated, and single-agent activity varied among NHL subtypes. We determined 1,200 mg to be the recommended single-agent dose for future studies in FL and DLBCL, with 800 mg being sufficient to consistently achieve durable response in MCL. Additional investigations including combination therapy to augment response rates and durability are ongoing.
引用
- Davids MS, Roberts AW, Seymour JF, et al. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. J Clin Oncol. 2017. PMID: 28095146. doi:10.1200/JCO.2016.70.4320
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。